Land: USA
Språk: engelska
Källa: NLM (National Library of Medicine)
nebivolol hydrochloride (UNII: JGS34J7L9I) (nebivolol - UNII:030Y90569U)
Avera McKennan Hospital
nebivolol hydrochloride
nebivolol 5 mg
PRESCRIPTION DRUG
New Drug Application
BYSTOLIC- NEBIVOLOL HYDROCHLORIDE TABLET AVERA MCKENNAN HOSPITAL ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE BYSTOLIC SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR BYSTOLIC. BYSTOLIC (NEBIVOLOL) TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 2007 INDICATIONS AND USAGE BYSTOLIC is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) DOSAGE AND ADMINISTRATION Can be taken with and without food. Individualize to the needs of the patient and monitor during up-titration. (2) Hypertension: Most patients start at 5 mg once daily. Dose can be increased at 2-week intervals up to 40 mg. (2.1) DOSAGE FORMS AND STRENGTHS Tablets: 2.5, 5, 10, 20 mg (3) CONTRAINDICATIONS Severe bradycardia (4) Heart block greater than first degree (4) Patients with cardiogenic shock (4) Decompensated cardiac failure (4) Sick sinus syndrome (unless a permanent pacemaker is in place) (4) Patients with severe hepatic impairment (Child-Pugh >B) (4) Hypersensitive to any component of this product (4) WARNINGS AND PRECAUTIONS Acute exacerbation of coronary artery disease upon cessation of therapy: Do not abruptly discontinue (5.1) Diabetes: Monitor glucose as β-blockers may mask symptoms of hypoglycemia (5.5) ADVERSE REACTIONS MOST COMMON ADVERSE REACTIONS (6.1): Headache, fatigue TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT FOREST LABORATORIES, INC. AT 1-800-678-1605 OR FDA AT 1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH. DRUG INTERACTIONS CYP2D6 enzyme inhibitors may increase nebivolol levels (7.1) Reserpine or clonidine may produce excessive reduction of sympathetic activity. (7.2) Both digitalis glycosides and β-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. (7.3) Verapamil- or diltiazem-type calcium channel Läs hela dokumentet